Table 2 Management and outcome of patients hospitalized in ICU with COVID-19
From: Secondary respiratory early and late infections in mechanically ventilated patients with COVID-19
All patients N = 175 | No respiratory secondary infection N = 104 | Respiratory secondary infection N = 71 | P value | |
|---|---|---|---|---|
In-hospital use of dexamethasonea | 68 (38.9) | 33 (31.7) | 35 (49.3) | 0.019 |
In-hospital use of methylprednisolone bolusesa | 72 (42.1) | 43 (41.3) | 29 (43.3) | 0.802 |
In-hospital use of tocilizumab | 22 (12.6) | 13 (12.4) | 9 (12.7) | 0.972 |
In-hospital use of ruxolitinib | 5 (2.9) | 3 (2.9) | 2 (2.8) | 0.979 |
Awake proning | 71 (43.8) | 42 (44.2) | 29 (43.3) | 0.907 |
Proning in MV | 126 (72,8) | 72 (70.6) | 54 (76.1) | 0.426 |
ECMO | 10 (5.7) | 4 (3.9) | 6 (8.8) | 0.183 |
Tracheostomya | 29 (16.7) | 13 (12.6) | 16 (22.5) | 0.085 |
Renal replacement therapy | 24 (14.3) | 12 (11.5) | 12 (16.9) | 0.311 |
Vasoactive drugs | 133 (77.3) | 68 (67.3) | 65 (91.5) | < 0.001 |
ICU re-admission | 5 (2.9) | 1 (1) | 4 (5.6) | 0.068 |
Length of prone position, days | 6 [3–10] | 5 [2–9] | 6 [3–11] | 0.221 |
Length hospital stay, days | 33 [21–52] | 30 [20–44] | 46 [32–76] | < 0.0001 |
Length ICU stay, days | 18 [9–33] | 16 [10–23] | 26 [15–51] | < 0.0001 |
Length MV, days | 14 [9–30] | 13 [9–22] | 23 [13–48] | < 0.0001 |
Time from admission to death, days | 25 [19–36] | 21 [16–30] | 33 [22–47] | 0.0062 |
Death at 28 days | 31 (17.7) | 20 (19) | 11 (15.5) | 0.526 |
Death in ICU | 54 (30.9) | 30 (28.8) | 24 (33.8) | 0.486 |
Case fatality rate | – | 30/100 | 34/100 | 0.485 |